Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Bakris, GL; Ruilope, L; Locatelli, F; Ptaszynska, A; Pieske, B; Raz, I; Voors, AA; Dechamplain, J; Weber, MA.
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
J Hum Hypertens. 2006; 20(9):693-700 Doi: 10.1038/sj.jhh.1002050 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Co-Autor*innen der Med Uni Graz
Pieske Burkert Mathias
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Declining kidney function predicts increasing cardiovascular risk in people with hypertension. Microalbuminuria is a marker for cardiovascular risk and declining kidney function. Agents that block the renin-angiotensin-aldosterone system (RAAS), notably angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), reduce proteinuria and microalbuminuria, lower blood pressure and slow the progression of proteinuric kidney disease. Evidence is accumulating that the combination of an ACE inhibitor and an ARB is the optimal means of RAAS blockade in this setting, slowing the progression of nephropathy independently of blood pressure lowering to a greater degree than can be achieved using maximum approved doses of either agent alone. However, the emerging therapeutic potential of ACE inhibitor/ARB combination therapy in hypertensive kidney disease requires further characterization. The Irbesartan in the Management of PROteinuric patients at high risk for Vascular Events trial aims to determine definitively whether the combination therapy of an ARB, irbesartan and an ACE inhibitor, ramipril, is more effective than ramipril alone in reducing the urinary albumin excretion rate in patients at high cardiovascular risk with hypertension and proteinuria or microalbuminuria.
Find related publications in this database (using NLM MeSH Indexing)
Angiotensin Receptor Antagonists -
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Dose-Response Relationship, Drug -
Evaluation Studies as Topic -
Female -
Humans -
Hypertension - blood Hypertension - drug therapy Hypertension - physiopathology
Male -
Middle Aged -
Proteinuria - blood Proteinuria - drug therapy Proteinuria - physiopathology
Risk Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
angiotensin-converting enzyme (ACE) inhibitor
angiotensin II receptor blocker
microalbuminuria
proteinuria
renoprotection
© Med Uni Graz Impressum